Indeed, various studies have shown that inhibition of CXCR4 results in anti-fibrotic effects in vitro and ameliorated bleomycin induced lung fibrosis in vivo22–26, suggesting that this chemokine receptor might be a therapeutic target in fibrotic lung diseases. Here, CXCR4 is linked to pulmonary fibrosis.